Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Report 2026

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size has grown strongly in recent years. It will grow from $9.44 billion in 2025 to $10.23 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of smoking related respiratory disorders, rising misdiagnosis of asthma and COPD overlap conditions, limited treatment personalization in respiratory care, growing hospital admissions due to exacerbations, dependence on conventional inhalation therapies.

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size is expected to see strong growth in the next few years. It will grow to $14.27 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expansion of biologics in respiratory disease management, increasing adoption of digital respiratory monitoring devices, rising demand for personalized treatment regimens, growth in home based chronic disease management, advancement in targeted anti inflammatory therapies. Major trends in the forecast period include personalized precision therapy for asthma-COPD overlap phenotypes, digital inhaler adherence monitoring and connected respiratory care, rise of biologic-based treatment for eosinophilic airway inflammation, integration of remote patient monitoring in chronic respiratory disease management, shift toward combination inhalation therapies for optimized airway control.

The increase in smoking-induced cases is anticipated to drive the expansion of asthma chronic obstructive pulmonary disease (COPD) overlap treatment in the coming years. Smoking-induced cases refer to occurrences of respiratory conditions, such as asthma or COPD, that primarily arise due to tobacco smoking. Smoking-induced cases are increasing because of the growing prevalence of tobacco product usage, which leads to lung inflammation, airway injury, and an elevated likelihood of developing long-term respiratory disorders. Asthma-COPD overlap treatment manages smoking-induced cases by offering targeted therapeutic approaches that concurrently control combined symptoms, airflow restrictions, and lung damage resulting from tobacco exposure, thereby enhancing respiratory performance and overall quality of life for individuals affected by both asthma and COPD. For instance, in February 2026, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic obstructive pulmonary disease (COPD) accounted for 3.7% of Australia’s total disease burden in 2024 and was the primary cause of 7,437 deaths in 2023, equivalent to 28 deaths per 100,000 population, representing 4.1% of all deaths. Therefore, the rise in smoking cases is projected to drive the expansion of the asthma COPD overlap treatment market.

The increasing demand for precision medicine is expected to drive the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in the future. Precision medicine is a healthcare approach that tailors treatment according to individual patient attributes such as genetics, biomarkers, and disease characteristics. The demand for precision medicine is rising due to improvements in biomarker discovery and molecular diagnostic technologies, which allow more accurate classification of respiratory diseases and more precise selection of targeted therapies. Precision medicine supports the identification of specific patient phenotypes and underlying inflammatory mechanisms in asthma-chronic obstructive pulmonary disease (COPD) overlap, enabling healthcare professionals to customize targeted treatment plans, improve therapeutic outcomes, reduce exacerbation frequency, and enhance overall disease control through individualized care approaches. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, representing a significant increase compared to the six approvals recorded in 2022. Therefore, the rising demand for precision medicine is contributing to the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market.

The growing elderly population is expected to drive the expansion of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in the coming years. The elderly population refers to individuals aged 65 years and above who are more prone to chronic health conditions due to age-related physiological decline. The elderly population is increasing due to rising life expectancy and decreasing fertility rates, resulting in a larger proportion of older individuals within the total population. Asthma-chronic obstructive pulmonary disease (COPD) overlap treatment supports better management of respiratory symptoms in the elderly population by providing customized therapies that address complex disease patterns, reduce exacerbation episodes, improve lung function, and enhance overall quality of life in older adults. For instance, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the global population aged 60 years and older is growing rapidly due to increased life expectancy and declining birth rates, with older adults expected to surpass younger age groups in many regions by 2030. Therefore, the increasing elderly population is driving the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market.

Major companies operating in the asthma-chronic obstructive pulmonary disease (copd) overlap treatment market are Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline plc, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Grifols S. A., Sun Pharmaceutical Industries Limited, Chiesi Farmaceutici S. p. A., Kyowa Kirin Co. Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Theravance Biopharma Inc., Orion Corporation.

North America was the dominating region in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market consists of revenues earned by entities by providing services such as pulmonary function testing, medication management, inhaler therapy training, oxygen therapy, pulmonary rehabilitation, patient education, telemedicine consultations, follow-up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market also includes sales of inhalers, nebulizers, bronchodilators, corticosteroid inhalers, combination inhalers, dry powder inhalers, and metered-dose inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.